Independent Phase II and III Clinical Studies on 22nd Century’s Smoking Cessation Technology Highlighted on New Heracles Website

Heracles Pharma Seeks to Develop Strategic Partnerships with Pharmaceutical Industry in Pursuit of FDA Approval and Commercialization of X-22 Very Low Nicotine Smoking Cessation Product CLARENCE, N.Y. XXII, (BUSINESS WIRE)  22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website atwww.heraclespharma.com to highlight the Company’s X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22 The post Independent Phase II and III Clinical Studies on 22nd Century s Smoking Cessation Technology Highlighted on New Heracles Website appeared first on Public Wire.
http://bit.ly/1TUYhVx

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: